RecruitingPhase 1NCT03739411

Hyperpolarized Imaging in Diagnosing Participants With Glioma

Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients With Gliomas


Sponsor

Susan Chang

Enrollment

140 participants

Start Date

Dec 9, 2015

Study Type

INTERVENTIONAL

Conditions

Summary

This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Chemotherapy, Hyperpolarized Carbon C 13 Pyruvate, and others for people with glioma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONHyperpolarized Carbon C 13 Pyruvate

Given IV

PROCEDUREMagnetic Resonance Imaging

Undergo MRI

RADIATIONRadiation Therapy

Undergo radiation therapy for cancer outside of this study.

DRUGChemotherapy

Undergo chemotherapy for cancer outside of this study.


Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03739411


Related Trials